Most-Read Print Stories of 2022

This year's most-read print stories from our monthly publication include 'Paxlovid Rebound: Rare But Real,' 'Diabetes Medications Find New Life as Weight-Loss Drugs,' 'Health Plans Prepare to Post Prices for Consumers,' and more.

  1. Paxlovid Rebound: Rare But Real
    Mayo Clinic researchers reported today in the journal Clinical Infectious Diseases that less than 1% of patients at high risk for experiencing severe COVID-19 who were treated with Paxlovid (nirmatrelvir and ritonavir) experienced a second bout of COVID-19.
    Read more
  2. Diabetes Medications Find New Life as Weight-Loss Drugs
    Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite. But their cost-effectiveness is in question, and many payers are saying no to coverage — for now.
    Read more
  3. Childhood Insomnia Symptoms Often Persist into Adulthood, Study Finds
    Children with poor sleep had a 2.6-fold higher risk of developing adult insomnia, according to longitudinal research conducted by Penn State researchers.
    Read more
  4. Multiple Sclerosis - Some Drugs New, Some Tried-and-True
    The race is on to be the first-approved Bruton tyrosine kinase inhibitor. Meanwhile, trials are underway to test statins and metformin as treatments for multiple sclerosis.
    Read more
  5. Health Plans Prepare to Post Prices for Consumers
    Price-transparency rule allows insurers to cut MLR payments by using incentives to encourage consumers to choose low-cost, high-value providers.
    Read more